Healthcare needs the digital treatment

The diagnosis for technological intervention in the delivery of healthcare services has been made, but the prescription hasn’t yet been written.

Over the last 50 years, the global healthcare bill has outgrown global GDP. The most extreme rise in costs has taken place in the US, where total healthcare costs have outgrown national GDP since the 1970s and, in 2019, the annual bill amounted to 18% of output. In Europe, healthcare costs as percentage of GDP are lower than in the US, as the European average sits at 9.9%, ranging from 5.3% in Luxembourg to 11.9% in Switzerland. However, costs have also risen steadily. Without changes to the healthcare system, costs will simply continue to outgrow GDP due to a raft of  inefficiencies, such as the decentralised nature of many healthcare systems, flawed incentive structures, and a focus on treatment over prevention. This situation stands to be exacerbated by the ageing of societies and the growing number of chronically ill patients.

The majority of healthcare costs are spent in the last years of life and, due the ageing of societies, the number of people reaching that point will increase substantially in the coming years. On top of that, the incidence of serious illness tends to increase with age. In 2019, 60% of adults in the US had one or more chronic conditions that required lifelong, and therefore expensive, treatment. Of the country’s total healthcare bill of USD 4 trillion, already USD 2.5 trillion is spend on treating chronic diseases, and ageing will only increase this spend.

Dementia, Parkinson’s disease and arthritis are among the causes of medical dependency that become more prevalent with age. These conditions require far longer treatment than cancer or heart disease, where the demise of patients can unfortunately occur more rapidly if therapy is unsuccessful. Capacity for dementia care in most Western countries is not sufficient to treat the rapidly growing number of patients with dementia, and especially Alzheimer’s disease. Treatments are perhaps advancing, but rapidly ageing societies will still substantially increase the costs of medical care of the elderly, especially given the long duration of conditions like dementia.

The focus now needs to be on how to reduce healthcare costs and build a more efficient system before we reach a breaking point. We believe the answer lies with digitalisation. From payments to dating and from autos to shopping, digitalisation is already being embraced by most parts of society. However, the conservative healthcare industry has been very hesitant to welcome the disruptive forces of digitalisation. With the use of proven digital tools, health technology has the potential to lower costs and improve outcomes.

We believe that there are three trends set to transform healthcare for the better. There is the growing prevalence of connected care, which has only been exacerbated by the pandemic. Doctors have consulted many patients online and people recovering from coronavirus at home have been monitored remotely by doctors via connected medical devices. Connecting to a physician via telehealth will become the norm just as wearing connected devices that constantly measure vital signs. Continuous Glucose Measuring devices have already changed the life of many type 1 diabetes patients, for example.

We also anticipate there will be a much greater focus on prevention. The healthcare system will adopt a greater focus on prevention through the use of better and earlier diagnostics, personal medicine and lifestyle changes. Research conducted by the Bipartican Policy Center suggests a combination of regular exercise and a healthy diet can help avoid 50% of all chronic diseases today. General practitioners, lifestyle coaches and psychotherapists are engaged in trying to improve peoples’ lifestyles and prevent obesity-related or other chronic diseases.

Finally, we expect the trend towards greater efficiency to accelerate. It is our view that the healthcare system can become simpler, faster and more affordable by embracing automation, artificial intelligence and outsourcing. There is clear potential for artificial intelligence to lower the cost and increase the efficiency of radiology services, or for researching new treatments, especially since the algorithms can interrogate digital copies of our DNA. Robots can easily provide more assistance in surgery than the roughly 20 procedures they are programmed to do today. Many more automated healthcare services need to be developed and rolled out this decade and, furthermore, be embraced in an industry that has been somewhat resistant to the notion.

The digital genie is out of the bottle for good. In the consumer services and manufacturing sectors, its powers have simplified processes, eliminated middlemen and, above all, lowered costs. The healthcare system is in sore need of this treatment.

Il presente documento è pubblicato da Lombard Odier Asset Management (Europe) Limited, una società autorizzata e regolamentata dalla Financial Conduct Authority (“FCA”), iscritta nel registro FCA con il numero 515393.
Lombard Odier Investment Managers (“LOIM”) è un marchio commerciale.
Questo documento è fornito esclusivamente a scopo informativo e non costituisce un’offerta o una raccomandazione di acquisto o vendita di titoli o servizi. Il presente documento non è destinato a essere distribuito, pubblicato o utilizzato in qualunque giurisdizione in cui tale distribuzione, pubblicazione o utilizzo fossero illeciti. Il presente documento non contiene raccomandazioni o consigli personalizzati e non intende sostituire un'assistenza professionale in materia di investimenti in prodotti finanziari Prima di effettuare una transazione qualsiasi, l’investitore dovrebbe valutare attentamente se l’operazione è idonea alla propria situazione personale e, ove necessario, richiedere una consulenza professionale indipendente riguardo ai rischi e a eventuali conseguenze legali, normative, creditizie, fiscali e contabili. Il presente documento è proprietà di LOIM ed è rivolto al destinatario esclusivamente per uso personale. Il presente documento non può essere riprodotto (in tutto o in parte), trasmesso, modificato o utilizzato per altri fini senza la previa autorizzazione scritta di LOIM. Questo documento riporta le opinioni di LOIM alla data di pubblicazione.
Né il presente documento né copie di esso possono essere inviati, portati o distribuiti negli Stati Uniti d’America, nei loro territori e domini o in aree soggette alla loro giurisdizione, oppure a o a favore di US Person. A tale proposito, con l’espressione “US Person” s’intende un soggetto avente cittadinanza, nazionalità o residenza negli Stati Uniti d’America, una società di persone costituita o esistente in uno qualsiasi degli stati, dei territori, o dei domini degli Stati Uniti d’America, o una società di capitali disciplinata dalle leggi degli Stati Uniti o di un qualsiasi loro stato, territorio o dominio, o ogni patrimonio o trust il cui reddito sia soggetto alle imposte federali statunitensi, indipendentemente dal luogo di provenienza.
Fonte dei dati: se non indicato diversamente, i dati sono elaborati da LOIM.
Alcune informazioni sono state ottenute da fonti pubbliche ritenute attendibili, ma in assenza di una verifica indipendente non possiamo garantire la loro correttezza e completezza.
I giudizi e le opinioni qui espresse hanno esclusivamente scopo informativo e non costituiscono una raccomandazione di LOIM a comprare, vendere o conservare un titolo. I giudizi e le opinioni sono validi alla data della presentazione, possono essere soggetti a modifiche e non devono essere intesi come una consulenza di investimento.
Il presente documento non può essere (i) riprodotto, fotocopiato o duplicato, in alcuna forma o maniera, né (ii) distribuito a persone che non siano dipendenti, funzionari, amministratori o agenti autorizzati del destinatario, senza il previo consenso di Lombard Odier Asset Management (Europe) Limited . Nel Regno Unito, questo documento rappresenta materiale di marketing ed è stato approvato da Lombard Odier Asset Management (Europe) Limited, che è autorizzata e regolamentata dalla FCA. ©2021 Lombard Odier IM. Tutti i diritti riservati.